zh 卢夫特韦

卢夫特韦
法律規範狀態
法律規範	美：Investigational drug;
识别信息
	IUPAC命名法 [(3S)-3-[(2S)-2-[(4-methoxy-1H-indol-2-yl)formamido]-4-methylpentanamido]-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butoxy]phosphonic acid; ;
CAS号	2468015-78-1
PubChem CID	154699467;
DrugBank	DB16514;
UNII	XJ51YOB1SC;
KEGG	D12172;
ChEBI	CHEBI:173073;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID501337108 ;
化学信息
化学式	C24H33N4O9P
摩尔质量	552.52 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC;
	InChI InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1; Key:FQKALOFOWPDTED-WBAXXEDZSA-N;

卢夫特韦（英语：Lufotrelvir、PF-07304814）是辉瑞公司开发的一种抗病毒药物，可作为3CL 蛋白酶抑制剂。^[1]它是一种前体药物，其磷酸基团在体内被裂解以产生活性剂PF-00835231。^[2]卢夫特韦正在用于治疗COVID-19的人体临床试验中，并显示出对COVID-19的良好活性，包括几种变异株，但与相关药物奈玛特韦不同，它没有口服活性，必须通过静脉注射给药，因此一直总体而言，临床开发中不太受欢迎的候选者。^[3]^[4]^[5]

参见

参考文献

^ Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Journal of Medicinal Chemistry. November 2020, 63 (21): 12725–12747. PMC 7571312 . PMID 33054210. doi:10.1021/acs.jmedchem.0c01063.
^ Boras, Britton; Jones, Rhys M.; Anson, Brandon J.; Arenson, Dan; Aschenbrenner, Lisa; Bakowski, Malina A.; Beutler, Nathan; Binder, Joseph; Chen, Emily; Eng, Heather; Hammond, Holly. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications. 2021-10-18, 12 (1): 6055. Bibcode:2021NatCo..12.6055B. ISSN 2041-1723. PMC 8523698 . PMID 34663813. doi:10.1038/s41467-021-26239-2 （英语）.
^ de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, et al. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL^pro inhibitor PF-00835231 as a potential new treatment for COVID-19. Journal of Virology. February 2021, 95 (10). PMC 8139662 . PMID 33622961. doi:10.1128/JVI.01819-20.
^ Baig MH, Sharma T, Ahmad I, Abohashrh M, Alam MM, Dong JJ. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study. Molecules. March 2021, 26 (6): 1678. PMC 8002701 . PMID 33802860. doi:10.3390/molecules26061678 .
^ Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Current Opinion in Virology. August 2021, 49: 36–40. PMC 8075814 . PMID 34029993. doi:10.1016/j.coviro.2021.04.006.

[1] Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Journal of Medicinal Chemistry. November 2020, 63 (21): 12725–12747. PMC 7571312 . PMID 33054210. doi:10.1021/acs.jmedchem.0c01063.

[2] Boras, Britton; Jones, Rhys M.; Anson, Brandon J.; Arenson, Dan; Aschenbrenner, Lisa; Bakowski, Malina A.; Beutler, Nathan; Binder, Joseph; Chen, Emily; Eng, Heather; Hammond, Holly. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications. 2021-10-18, 12 (1): 6055. Bibcode:2021NatCo..12.6055B. ISSN 2041-1723. PMC 8523698 . PMID 34663813. doi:10.1038/s41467-021-26239-2 （英语）.

[3] Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, et al. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL^pro inhibitor PF-00835231 as a potential new treatment for COVID-19. Journal of Virology. February 2021, 95 (10). PMC 8139662 . PMID 33622961. doi:10.1128/JVI.01819-20.

[4] Baig MH, Sharma T, Ahmad I, Abohashrh M, Alam MM, Dong JJ. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study. Molecules. March 2021, 26 (6): 1678. PMC 8002701 . PMID 33802860. doi:10.3390/molecules26061678 .

[5] Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Current Opinion in Virology. August 2021, 49: 36–40. PMC 8075814 . PMID 34029993. doi:10.1016/j.coviro.2021.04.006.

[1]

[2]

[3]

[4]

[5]

Agama	Bahasa	Biografi	Budaya	Ekonomi	Elektronika
Film	Filsafat	Geografi	Indonesia	Ilmu	Lingkungan
Masyarakat	Matematika	Militer	Mitologi	Musik	Olahraga
Pendidikan	Politik	Sastra	Sejarah	Seni	Teknologi

卢夫特韦

参见

参考文献

Portal di Ensiklopedia Dunia